Mon, 20 Apr 2026
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Terms of Use | Privacy Policy | Manage Cookies+ | Ad Choices | Accessibility & CC | About | Newsletters | Transcripts
Business News Top © 2024-2025